Outcome in transplant eligible patients with multiple myeloma in Latin America. An international study of GELAMM

Jun 15, 2019 | Artículos publicados por GELAMM, Publicaciones


Authors:
 

Camila Peña, Natalia P Schutz, Virginia Bove, Fiorella Villano, Rocío Osorio, Mauricio Chandía, Daniela Cardemil, Carolina Contreras, Carmen G Contreras, Javiera Donoso, Marcela Espinoza, La Rocca Gabriel, Hernán López-Vidal, Christine Rojas, Pablo Soto, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos Alen García, Vanesa Fernández, Dorotea Fantl, Eloísa Riva

Abstract:

Multiple myeloma (MM) is a frequent hematologic malignancy. Despite the important advances in treatment strategies during the last decades, the gold standard remains being a proteasome inhibitor (PI)-based induction, followed by autologous stem cell transplant (ASCT).

In Latin America (LA) there is great heterogeneity in access to new drugs and ASCT, and there is scarce data regarding patient ´s outcomes in the region.

Publication:

EHA Library. Peña C. 06/15/19; 267019; PS1402